Therapeutic Response

HRD, not BRCA1 oncogenic variants, not BRCA1 pathogenic variants, not BRCA2 oncogenic variants, and not BRCA2 pathogenic variants status confers therapeutic sensitivity to Rucaparib in patients with High-Grade Serous Fallopian Tube Cancer.

Statements

Source and description